{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:42:41Z","timestamp":1782538961063,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Proteasome inhibitors (PIs) are indispensable for the treatment of multiple myeloma (MM), the second most common hematologic malignancy. Although primary resistance to PIs is rare, most patients eventually relapse and develop acquired resistance, with underlying mechanisms that remain incompletely understood and appear to be drug-specific. In the case of bortezomib, resistance is often associated with\n                      <jats:italic>PSMB5<\/jats:italic>\n                      mutations. In contrast, resistance to carfilzomib (CFZ) is mediated by overexpression of the drug efflux transporter ABCB1. However, the regulatory mechanisms driving ABCB1 upregulation in CFZ-resistant MM remain unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An integrative multi-omics analysis was conducted using paired samples from a CFZ-sensitive and -resistant MM patient, alongside resistant cell line models. Whole-genome sequencing (WGS), whole-genome bisulfite sequencing (WGBS), and RNA sequencing (RNA-seq) were used to assess the genotype (structural variants, single nucleotide variants, and copy number variations), methylation status, and the expression of the\n                      <jats:italic>ABCB1<\/jats:italic>\n                      locus.\n                      <jats:italic>ABCB1<\/jats:italic>\n                      promoter methylation levels and expression levels in an independent MM subcohort were analyzed to determine clinical relevance. Functional validation was performed using dual-luciferase reporter assays,\n                      <jats:italic>DNMT1<\/jats:italic>\n                      knockdown, and treatment with DNA methyltransferase inhibitors (DNMTis) to evaluate methylation-dependent regulation of\n                      <jats:italic>ABCB1<\/jats:italic>\n                      expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant hypomethylation of the\n                      <jats:italic>ABCB1<\/jats:italic>\n                      downstream promoter region was identified (GH07J087598) in a CFZ-resistant patient sample, which correlated with elevated\n                      <jats:italic>ABCB1<\/jats:italic>\n                      expression. Consistent with the paired CFZ-resistant case, the independent MM subcohort showed a significant inverse association between\n                      <jats:italic>ABCB1<\/jats:italic>\n                      promoter methylation and\n                      <jats:italic>ABCB1<\/jats:italic>\n                      expression. These findings align with results obtained from CFZ-resistant MM cell line models, which demonstrated reduced promoter methylation and elevated\n                      <jats:italic>ABCB1<\/jats:italic>\n                      expression compared to their wild-type counterparts. Furthermore, treatment with DNA methyltransferase inhibitors as well as\n                      <jats:italic>DNMT1<\/jats:italic>\n                      knockdown enhanced\n                      <jats:italic>ABCB1<\/jats:italic>\n                      expression while demethylating the promoter, thereby validating the functional significance of promoter hypomethylation in\n                      <jats:italic>ABCB1<\/jats:italic>\n                      overexpression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings highlight\n                      <jats:italic>ABCB1<\/jats:italic>\n                      promoter hypomethylation as a potential epigenetic driver of CFZ resistance in MM. These results underscore the clinical relevance of epigenetic regulation in drug resistance and the potential of targeting DNA methylation as a therapeutic strategy to overcome resistance in MM.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-026-02115-y","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:46:27Z","timestamp":1775065587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-3102","authenticated-orcid":false,"given":"Seungbin","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-9163","authenticated-orcid":false,"given":"Larissa","family":"Haertle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Munawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Truger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sophie","family":"Hainold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Verbruggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nerreter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Besant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Rein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"K\u00f6ppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tamamushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Steinbrunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Haaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"K\u00fcster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Slaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1818","authenticated-orcid":false,"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-2959","authenticated-orcid":false,"given":"Andrej","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1124-7303","authenticated-orcid":false,"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-7618","authenticated-orcid":false,"given":"Lenka","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"9","key":"2115_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"key":"2115_CR2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.","journal-title":"Nat Rev Dis Primers"},{"issue":"4\u20135","key":"2115_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","volume":"11","author":"DJ McConkey","year":"2008","unstructured":"McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11(4\u20135):164\u201379.","journal-title":"Drug Resist Updat"},{"issue":"21","key":"2115_CR4","doi-asserted-by":"publisher","first-page":"11595","DOI":"10.3390\/ijms222111595","volume":"22","author":"J Wang","year":"2021","unstructured":"Wang J, Fang Y, Fan RA, Kirk CJ. Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism. Int J Mol Sci. 2021;22(21):11595.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2115_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561\u201384.","journal-title":"Cancer Metastasis Rev"},{"issue":"17","key":"2115_CR6","first-page":"4082","volume":"14","author":"D Dima","year":"2022","unstructured":"Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, et al. Multiple myeloma therapy: emerg trends challenges cancers. 2022;14(17):4082.","journal-title":"Multiple myeloma therapy: emerg trends challenges cancers"},{"issue":"22","key":"2115_CR7","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","volume":"22","author":"KC Anderson","year":"2016","unstructured":"Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22(22):5419\u201327.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2115_CR8","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/cancers15061682","volume":"15","author":"P Weir","year":"2023","unstructured":"Weir P, Donaldson D, McMullin MF, Crawford L. Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance. Cancers. 2023;15(6):1682.","journal-title":"Cancers"},{"issue":"4","key":"2115_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","volume":"124","author":"M Ge","year":"2021","unstructured":"Ge M, Qiao Z, Kong Y, Liang H, Sun Y, Lu H, et al. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. Br J Cancer. 2021;124(4):770\u20136.","journal-title":"Br J Cancer"},{"key":"2115_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015;18:18\u201335.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"2115_CR11","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","volume":"35","author":"K Allmeroth","year":"2021","unstructured":"Allmeroth K, Horn M, Kroef V, Miethe S, Muller RU, Denzel MS. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia. 2021;35(3):887\u201392.","journal-title":"Leukemia"},{"issue":"5","key":"2115_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0969-2126(02)00748-7","volume":"10","author":"M Unno","year":"2002","unstructured":"Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, et al. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure. 2002;10(5):609\u201318.","journal-title":"Structure"},{"issue":"1","key":"2115_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-22-1161","volume":"29","author":"L Haertle","year":"2023","unstructured":"Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, et al. Single-nucleotide variants and epimutations induce proteasome inhibitor resistance in multiple myeloma. Clin Cancer Res. 2023;29(1):279\u201388.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2115_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2017.212","volume":"32","author":"A Besse","year":"2018","unstructured":"Besse A, Stolze SC, Rasche L, Weinhold N, Morgan GJ, Kraus M, et al. Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia. 2018;32(2):391\u2013401.","journal-title":"Leukemia"},{"issue":"1","key":"2115_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/14622416.9.1.105","volume":"9","author":"FJ Sharom","year":"2008","unstructured":"Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105\u201327.","journal-title":"Pharmacogenomics"},{"key":"2115_CR16","doi-asserted-by":"publisher","first-page":"106499","DOI":"10.1016\/j.leukres.2020.106499","volume":"101","author":"K Byrgazov","year":"2021","unstructured":"Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, et al. Up-regulation of multidrug resistance protein MDR1\/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leuk Res. 2021;101:106499.","journal-title":"Leuk Res"},{"issue":"45","key":"2115_CR17","doi-asserted-by":"publisher","first-page":"73347","DOI":"10.18632\/oncotarget.12332","volume":"7","author":"M Spitzwieser","year":"2016","unstructured":"Spitzwieser M, Pirker C, Koblmuller B, Pfeiler G, Hacker S, Berger W, et al. Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget. 2016;7(45):73347\u201369.","journal-title":"Oncotarget"},{"key":"2115_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1186\/s12885-015-1689-8","volume":"15","author":"R Demidenko","year":"2015","unstructured":"Demidenko R, Razanauskas D, Daniunaite K, Lazutka JR, Jankevicius F, Jarmalaite S. Frequent down-regulation of ABC transporter genes in prostate cancer. BMC Cancer. 2015;15:683.","journal-title":"BMC Cancer"},{"issue":"3","key":"2115_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4161\/epi.1.3.3327","volume":"1","author":"M Klug","year":"2006","unstructured":"Klug M, Rehli M. Functional analysis of promoter CPG-methylation using a CpG-free luciferase reporter vector. Epigenetics. 2006;1(3):127\u201330.","journal-title":"Epigenetics"},{"issue":"11","key":"2115_CR20","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016;30(11):2198\u2013207.","journal-title":"Leukemia"},{"issue":"1","key":"2115_CR21","first-page":"7","volume":"60","author":"RR Parrish","year":"2012","unstructured":"Parrish RR, Day JJ, Lubin FD. Direct bisulfite sequencing for examination of DNA methylation with gene and nucleotide resolution from brain tissues. Curr Protoc Neurosci. 2012;60(1):7\u201324.","journal-title":"Curr Protoc Neurosci"},{"issue":"16","key":"2115_CR22","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1182\/blood.2022015909","volume":"140","author":"S Gooding","year":"2022","unstructured":"Gooding S, Ansari-Pour N, Kazeroun M, Karagoz K, Polonskaia A, Salazar M, et al. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 2022;140(16):1816\u201321.","journal-title":"Blood"},{"issue":"3","key":"2115_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289\u2013304.","journal-title":"Cancer Cell"},{"issue":"9","key":"2115_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kortum","year":"2016","unstructured":"Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226\u201333.","journal-title":"Blood"},{"issue":"18","key":"2115_CR25","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.2020010452","volume":"138","author":"L Haertle","year":"2021","unstructured":"Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. 2021;138(18):1721\u20136.","journal-title":"Blood"},{"issue":"2","key":"2115_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2024026622","volume":"146","author":"S Ma","year":"2025","unstructured":"Ma S, Xia J, Zhang M, Li W, Xiao M, Sha Y, et al. Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma. Blood. 2025;146(2):178\u201390.","journal-title":"Blood"},{"issue":"11","key":"2115_CR27","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023;4(11):1536\u201343.","journal-title":"Nat Cancer"},{"key":"2115_CR28","doi-asserted-by":"crossref","unstructured":"Han S, Munawar U, Truger M, Gerhard-Hartmann E, Verbruggen C, Pfeiffer L et al. Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma. Haematologica. 2026.","DOI":"10.3324\/haematol.2025.289162"},{"issue":"2","key":"2115_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","volume":"33","author":"S Barrio","year":"2019","unstructured":"Barrio S, St\u00fchmer T, Da-Vi\u00e1 M, Barrio-Garcia C, Lehners N, Besse A, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia. 2019;33(2):447\u201356.","journal-title":"Leukemia"},{"issue":"1","key":"2115_CR30","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/s41598-020-63265-4","volume":"10","author":"I Zawadzka","year":"2020","unstructured":"Zawadzka I, Jelen A, Pietrzak J, Zebrowska-Nawrocka M, Michalska K, Szmajda-Krygier D, et al. The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy - preliminary report. Sci Rep. 2020;10(1):6188.","journal-title":"Sci Rep"},{"issue":"5","key":"2115_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4161\/epi.3.5.6868","volume":"3","author":"K Reed","year":"2008","unstructured":"Reed K, Hembruff SL, Laberge ML, Villeneuve DJ, C\u00f4t\u00e9 GB, Parissenti AM. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Epigenetics. 2008;3(5):270\u201380.","journal-title":"Epigenetics"},{"issue":"6","key":"2115_CR32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/iep.12212","volume":"97","author":"A Li","year":"2016","unstructured":"Li A, Song J, Lai Q, Liu B, Wang H, Xu Y, et al. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Int J Exp Pathol. 2016;97(6):412\u201321.","journal-title":"Int J Exp Pathol"},{"issue":"1","key":"2115_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.tvjl.2013.10.022","volume":"199","author":"H Tomiyasu","year":"2014","unstructured":"Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients. Vet J. 2014;199(1):103\u20139.","journal-title":"Vet J"},{"issue":"7378","key":"2115_CR34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature10716","volume":"480","author":"MB Stadler","year":"2011","unstructured":"Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Scholer A, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature. 2011;480(7378):490\u20135.","journal-title":"Nature"},{"issue":"7583","key":"2115_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature16462","volume":"528","author":"S Domcke","year":"2015","unstructured":"Domcke S, Bardet AF, Adrian Ginno P, Hartl D, Burger L, Schubeler D. Competition between DNA methylation and transcription factors determines binding of NRF1. Nature. 2015;528(7583):575\u20139.","journal-title":"Nature"},{"issue":"1","key":"2115_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/sj.onc.1206056","volume":"22","author":"M Bentires-Alj","year":"2003","unstructured":"Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22(1):90\u20137.","journal-title":"Oncogene"},{"issue":"11","key":"2115_CR37","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.leukres.2015.08.017","volume":"39","author":"YT Tsai","year":"2015","unstructured":"Tsai YT, Lozanski G, Lehman A, Sass EJ, Hertlein E, Salunke SB, et al. BRAF(V600E) induces ABCB1\/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leuk Res. 2015;39(11):1270\u20137.","journal-title":"Leuk Res"},{"issue":"3","key":"2115_CR38","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.18632\/oncotarget.6510","volume":"7","author":"EJ Choi","year":"2016","unstructured":"Choi EJ, Seo EJ, Kim DK, Lee SI, Kwon YW, Jang IH, et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget. 2016;7(3):3506\u201319.","journal-title":"Oncotarget"},{"issue":"4","key":"2115_CR39","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.3892\/mmr.2016.5658","volume":"14","author":"Y Cao","year":"2016","unstructured":"Cao Y, Qiu GQ, Wu HQ, Wang ZL, Lin Y, Wu W, et al. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells. Mol Med Rep. 2016;14(4):3469\u201375.","journal-title":"Mol Med Rep"},{"issue":"21","key":"2115_CR40","doi-asserted-by":"publisher","first-page":"8726","DOI":"10.1158\/0008-5472.CAN-10-0755","volume":"70","author":"H Huo","year":"2010","unstructured":"Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 2010;70(21):8726\u201335.","journal-title":"Cancer Res"},{"key":"2115_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.lfs.2018.11.043","volume":"216","author":"Y Yang","year":"2019","unstructured":"Yang Y, Zhang J, Wu T, Xu X, Cao G, Li H, et al. Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1. Life Sci. 2019;216:200\u20136.","journal-title":"Life Sci"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02115-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02115-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02115-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:36:30Z","timestamp":1775723790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02115-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2115"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02115-y","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the independent Cantonal Ethical Committee (EKOS09\/057) and by the Ethical Committee of Wuerzburg University (No. 8\/21). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable. No identifiable patient data are presented in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.W. has received personal fees from GSK, Menarini-Stemline, Pfizer, Takeda, Sanofi, Oncopeptides, Janssen, and Skyline Dx, as well as research support from BMS. H.E. reports grant funding and other support from Sanofi, Takeda, Novartis, BMS, GSK, Amgen, and Janssen. C.H. is a shareholder in and employee of MLL Munich Leukemia Laboratory. L.R. has received personal fees from Sanofi, Amgen, GSK, Janssen, Pfizer, and BMS. K.M.K. reports personal fees from GSK, Takeda, AbbVie, Celgene, and BMS, and has also received both grants and personal fees from Janssen. All remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}